P. A. de Graeff

808 total citations
27 papers, 594 citations indexed

About

P. A. de Graeff is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Pharmacology. According to data from OpenAlex, P. A. de Graeff has authored 27 papers receiving a total of 594 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 6 papers in Economics and Econometrics and 5 papers in Pharmacology. Recurrent topics in P. A. de Graeff's work include Cardiac electrophysiology and arrhythmias (7 papers), Pharmaceutical industry and healthcare (4 papers) and Heart Failure Treatment and Management (4 papers). P. A. de Graeff is often cited by papers focused on Cardiac electrophysiology and arrhythmias (7 papers), Pharmaceutical industry and healthcare (4 papers) and Heart Failure Treatment and Management (4 papers). P. A. de Graeff collaborates with scholars based in Netherlands, Germany and United Kingdom. P. A. de Graeff's co-authors include Wiek H. van Gilst, H. Wesseling, Egbert Scholtens, Jan van Wijngaarden, Dick de Zeeuw, Cees D. J. de Langen, Julia B. Lewis, Éric Abadie, Kristina Dunder and Giuseppe Remuzzi and has published in prestigious journals such as European Heart Journal, Diabetologia and Cardiovascular Research.

In The Last Decade

P. A. de Graeff

27 papers receiving 564 citations

Peers

Countries citing papers authored by P. A. de Graeff

Since Specialization

Citations

This map shows the geographic impact of P. A. de Graeff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. A. de Graeff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. A. de Graeff more than expected).

Fields of papers citing papers by P. A. de Graeff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. A. de Graeff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. A. de Graeff. The network helps show where P. A. de Graeff may publish in the future.

Co-authorship network of co-authors of P. A. de Graeff

This figure shows the co-authorship network connecting the top 25 collaborators of P. A. de Graeff. A scholar is included among the top collaborators of P. A. de Graeff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. A. de Graeff. P. A. de Graeff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk Attitudes and Personality Traits Predict Perceptions of Benefits and Risks for Medicinal Products: A Field Study of European Medical Assessors 2015 ·Value in Health ·(unknown), Barbara Fasolo, P. A. de Graeff, Hans L. Hillege	21
2	When Direct Health-Care Professional Communications Have an Impact on Inappropriate and Unsafe Use of Medicines 2012 ·Clinical Pharmacology & Therapeutics ·Katrin Christiane Reber, (unknown), Jaap E. Wieringa, Sabine M. J. M. Straus, June Raine, P. A. de Graeff, Flora M. Haaijer‐Ruskamp, Peter G. M. Mol	26
3	Impact of Safety-Related Regulatory Action on Drug Use in Ambulatory Care in the Netherlands 2012 ·Clinical Pharmacology & Therapeutics ·(unknown), Katrin Christiane Reber, Jaap E. Wieringa, Sabine M. J. M. Straus, P. A. de Graeff, Flora M. Haaijer‐Ruskamp, Peter G. M. Mol	24
4	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials 2011 ·European Heart Journal ·Frank A. Holtkamp, Dick de Zeeuw, P. A. de Graeff, Gozewijn D. Laverman, Tomás Berl, Giuseppe Remuzzi, David Packham, Julia B. Lewis, H.‐H. Parving, Hiddo J.L. Heerspink	95
5	Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter 2011 ·EP Europace ·Irina Savelieva, Paulus Kirchhof, N Danchin, P. A. de Graeff, A. John Camm	7
6	Rosiglitazone: a European regulatory perspective 2010 ·Diabetologia ·E. Blind, Kristina Dunder, P. A. de Graeff, Éric Abadie	38
7	Microalbuminuria is Related to Marked End Organ Damage in Previously Untreated, Elderly Hypertensive Patients 2002 ·Blood Pressure ·(unknown), Johan F. May, A. J. Smit, P. A. de Graeff, H. J. G. M. Crijns	15
8	Clinical relevance of the gap between pre-marketing trials and medical practice: the case of the cardiovascular drugs. 2002 ·PubMed ·(unknown), Petra Denig, P. A. de Graeff, (unknown)	1
9	Comparative trials in registration files of cardiovascular drugs: comparator drugs and dosing schemes. 2001 ·Pharmacy World & Science ·(unknown), (unknown), P. A. de Graeff	3
10	Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use 1999 ·European Journal of Clinical Pharmacology ·(unknown), P. A. de Graeff, (unknown), (unknown)	29
11	Predictive value of ambulatory blood pressure shortly after withdrawal of antihypertensive drugs in primary care patients 1996 ·BMJ ·Frank W. Beltman, Wilfred F. Heesen, (unknown), Andries J. Smit, Johan F. May, P. A. de Graeff, (unknown), (unknown), (unknown), K.I. Lie, Betty Meyboom‐de Jong	10
12	Effect of Ibopamine on Ventricular Remodeling After Experimental Myocardial Infarction 1994 ·Journal of Cardiovascular Pharmacology ·Wiek H. van Gilst, Dirk J. van Veldhuisen, (unknown), Hendrik Buikema, Egbert Scholtens, P. A. de Graeff, K.I. Lie	15
13	Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology 1993 ·Cardiovascular Research ·Y M Pinto, (unknown), Wiek H. van Gilst, Egbert Scholtens, Stefan H. J. Monnink, P. A. de Graeff, H. Wesseling	53
14	Effects of Early Angiotensin-Converting Enzyme Inhibition in a Pig Model of Myocardial Ischemia and Reperfusion 1992 ·Journal of Cardiovascular Pharmacology ·Jan van Wijngaarden, T Tobe, (unknown), Klaas J. Bel, P. A. de Graeff, (unknown), Wiek H. van Gilst, H. Wesseling	18
15	Coronary vasodilation induced by captopril and zofenoprilat: evidence for a prostaglandin-independent mechanism 1991 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Jan van Wijngaarden, René A. Tio, Wiek H. van Gilst, P. A. de Graeff, Cees D. J. de Langen, H. Wesseling	6
16	Basic pharmacology of ACE-inhibitors with respect to ischaemic heart disease: Prostaglandins and bradykinin 1990 ·European Heart Journal ·Jan van Wijngaarden, René A. Tio, Wiek H. van Gilst, P. A. de Graeff, Cees D. J. de Langen, H. Wesseling	29
17	Efficacy and safety of ibopamine in congestive heart failure 1990 ·Journal of Autonomic Pharmacology ·Dirk J. van Veldhuisen, (unknown), (unknown), Andries J. Smit, P. A. de Graeff, K.I. Lie	6
18	Acute and chronic effects of ramipril and captopril in congestive heart failure 1989 ·International Journal of Cardiology ·P. A. de Graeff, J.Herre Kingma, (unknown), H. Wesseling, K.I. Lie	12
19	Effects of intravenous captopril on inducible sustained ventricular tachycardia one week after experimental infarction in the anaesthetized pig. 1986 ·PubMed ·(unknown), P. A. de Graeff, Wiek H. van Gilst, Ellen van Binsbergen, C. D. Dé Langen, Hendrik Wesseling	34
20	Immune Response to Two Different Hepatitis B Vaccines in Haemodialysis Patients: A 2-Year Follow-Up 1985 ·The Nephron journals/Nephron journals ·P. A. de Graeff, (unknown), Dick de Zeeuw, Ch Gips, G. K. van der Hem	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact